Anti-TGF-beta Therapy in Patients With Myelofibrosis

Summary

TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation. This is a novel approach to the treatment of patients with myelofibrosis.

Timeline

Start

2011-02

Primary completion

2013-01

Completion

2013-01

Outcome

Outcome not reported

Stopped: “Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.”

Publications

• Results Mascarenhas J, Li T, Sandy L, Newsom C, Petersen B, Godbold J, Hoffman R. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk Lymphoma. 2014 Feb;55(2):450-2. doi: 10.3109/10428194.2013.805329. Epub 2013 Jun 24. No abstract available.

Drugs

Indications